메뉴 건너뛰기




Volumn 270, Issue 1, 2016, Pages 193-208

Harnessing T cells to fight cancer with BiTE® antibody constructs - past developments and future directions

Author keywords

Acute lymphoblastic leukemia; Acute myeloid leukemia; Bispecific T cell engager (BiTE ); Blinatumomab; Immunotherapy; Non Hodgkin's lymphoma

Indexed keywords

AMG 211; AMG 212; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; BLINATUMOMAB; MONOCLONAL ANTIBODY; SOLITOMAB; UNCLASSIFIED DRUG; TUMOR ANTIGEN;

EID: 84957647658     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12393     Document Type: Review
Times cited : (126)

References (117)
  • 1
    • 84894107349 scopus 로고    scopus 로고
    • New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape
    • Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol 2014;27:16-25.
    • (2014) Curr Opin Immunol , vol.27 , pp. 16-25
    • Mittal, D.1    Gubin, M.M.2    Schreiber, R.D.3    Smyth, M.J.4
  • 2
    • 84886698315 scopus 로고    scopus 로고
    • Innate and adaptive immune cells in the tumor microenvironment
    • Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013;14:1014-1022.
    • (2013) Nat Immunol , vol.14 , pp. 1014-1022
    • Gajewski, T.F.1    Schreiber, H.2    Fu, Y.X.3
  • 4
    • 84864140772 scopus 로고    scopus 로고
    • Protecting a serial killer: pathways for perforin trafficking and self-defence ensure sequential target cell death
    • Lopez JA, Brennan AJ, Whisstock JC, Voskoboinik I, Trapani JA. Protecting a serial killer: pathways for perforin trafficking and self-defence ensure sequential target cell death. Trends Immunol 2012;33:406-412.
    • (2012) Trends Immunol , vol.33 , pp. 406-412
    • Lopez, J.A.1    Brennan, A.J.2    Whisstock, J.C.3    Voskoboinik, I.4    Trapani, J.A.5
  • 5
    • 84944277572 scopus 로고    scopus 로고
    • Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells
    • Wu AA, Drake V, Huang HS, Chiu S, Zheng L. Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology 2015;4:e1016700.
    • (2015) Oncoimmunology , vol.4
    • Wu, A.A.1    Drake, V.2    Huang, H.S.3    Chiu, S.4    Zheng, L.5
  • 6
    • 0037448353 scopus 로고    scopus 로고
    • Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
    • Zhang L, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-213.
    • (2003) N Engl J Med , vol.348 , pp. 203-213
    • Zhang, L.1
  • 7
    • 33749319703 scopus 로고    scopus 로고
    • Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
    • Galon J, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-1964.
    • (2006) Science , vol.313 , pp. 1960-1964
    • Galon, J.1
  • 8
    • 84928759208 scopus 로고    scopus 로고
    • Adoptive cell transfer as personalized immunotherapy for human cancer
    • Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015;348:62-68.
    • (2015) Science , vol.348 , pp. 62-68
    • Rosenberg, S.A.1    Restifo, N.P.2
  • 9
    • 84943143291 scopus 로고    scopus 로고
    • Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology
    • Barbee MS, Ogunniyi A, Horvat TZ, Dang TO. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Ann Pharmacother 2015;49:907-937.
    • (2015) Ann Pharmacother , vol.49 , pp. 907-937
    • Barbee, M.S.1    Ogunniyi, A.2    Horvat, T.Z.3    Dang, T.O.4
  • 10
    • 84937707232 scopus 로고    scopus 로고
    • Chimeric antigen receptor- and TCR-modified T cells enter main street and wall street
    • Barrett DM, Grupp SA, June CH. Chimeric antigen receptor- and TCR-modified T cells enter main street and wall street. J Immunol 2015;195:755-761.
    • (2015) J Immunol , vol.195 , pp. 755-761
    • Barrett, D.M.1    Grupp, S.A.2    June, C.H.3
  • 11
    • 84962948025 scopus 로고    scopus 로고
    • Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials
    • [E-pub ahead of print].
    • Zhu Y, et al. Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials. Eur J Haematol 2015 [E-pub ahead of print].
    • (2015) Eur J Haematol
    • Zhu, Y.1
  • 12
    • 84936934575 scopus 로고    scopus 로고
    • Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer
    • Stieglmaier J, Benjamin J, Nagorsen D. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer. Exp Opin Biol Ther 2015;15:1093-1099.
    • (2015) Exp Opin Biol Ther , vol.15 , pp. 1093-1099
    • Stieglmaier, J.1    Benjamin, J.2    Nagorsen, D.3
  • 13
    • 0021832361 scopus 로고
    • Hybrid antibodies can target sites for attack by T cells
    • Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature 1985;314:628-631.
    • (1985) Nature , vol.314 , pp. 628-631
    • Staerz, U.D.1    Kanagawa, O.2    Bevan, M.J.3
  • 14
    • 79955662260 scopus 로고    scopus 로고
    • Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab
    • Nagorsen D, Baeuerle PA. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res 2011;317:1255-1260.
    • (2011) Exp Cell Res , vol.317 , pp. 1255-1260
    • Nagorsen, D.1    Baeuerle, P.A.2
  • 15
    • 28944434529 scopus 로고    scopus 로고
    • Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells
    • Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 2006;43:763-771.
    • (2006) Mol Immunol , vol.43 , pp. 763-771
    • Offner, S.1    Hofmeister, R.2    Romaniuk, A.3    Kufer, P.4    Baeuerle, P.A.5
  • 16
    • 64649103924 scopus 로고    scopus 로고
    • Mode of cytotoxic action of T cell-engaging BiTE antibody MT110
    • Haas C, et al. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 2009;214:441-453.
    • (2009) Immunobiology , vol.214 , pp. 441-453
    • Haas, C.1
  • 17
    • 58549109813 scopus 로고    scopus 로고
    • Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells
    • d'Argouges S, et al. Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leuk Res 2009;33:465-473.
    • (2009) Leuk Res , vol.33 , pp. 465-473
    • d'Argouges, S.1
  • 18
    • 0343415665 scopus 로고    scopus 로고
    • A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes
    • Loffler A, et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000;95:2098-2103.
    • (2000) Blood , vol.95 , pp. 2098-2103
    • Loffler, A.1
  • 19
    • 28744445538 scopus 로고    scopus 로고
    • MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors
    • Brischwein K, et al. MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol Immunol 2006;43:1129-1143.
    • (2006) Mol Immunol , vol.43 , pp. 1129-1143
    • Brischwein, K.1
  • 20
    • 37349123501 scopus 로고    scopus 로고
    • Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class
    • Brischwein K, et al. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother 2007;30:798-807.
    • (2007) J Immunother , vol.30 , pp. 798-807
    • Brischwein, K.1
  • 21
    • 0037143806 scopus 로고    scopus 로고
    • Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody
    • Dreier T, et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 2002;100:690-697.
    • (2002) Int J Cancer , vol.100 , pp. 690-697
    • Dreier, T.1
  • 22
    • 0031569465 scopus 로고    scopus 로고
    • Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity
    • Mack M, Gruber R, Schmidt S, Riethmuller G, Kufer P. Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity. J Immunol 1997;158:3965-3970.
    • (1997) J Immunol , vol.158 , pp. 3965-3970
    • Mack, M.1    Gruber, R.2    Schmidt, S.3    Riethmuller, G.4    Kufer, P.5
  • 23
    • 84902674948 scopus 로고    scopus 로고
    • Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia
    • Friedrich M, et al. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther 2014;13:1549-1557.
    • (2014) Mol Cancer Ther , vol.13 , pp. 1549-1557
    • Friedrich, M.1
  • 24
    • 34447643439 scopus 로고    scopus 로고
    • The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct
    • Brandl C, et al. The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct. Cancer Immunol Immunother 2007;56:1551-1563.
    • (2007) Cancer Immunol Immunother , vol.56 , pp. 1551-1563
    • Brandl, C.1
  • 25
    • 78149437871 scopus 로고    scopus 로고
    • Effector memory T cells make a major contribution to redirected target cell lysis by T cell-engaging BiTE antibody MT110
    • Kischel R, Hausmann S, Baeuerle P, Kufer P. Effector memory T cells make a major contribution to redirected target cell lysis by T cell-engaging BiTE antibody MT110. Cancer Res 2009;69:3252.
    • (2009) Cancer Res , vol.69 , pp. 3252
    • Kischel, R.1    Hausmann, S.2    Baeuerle, P.3    Kufer, P.4
  • 26
    • 84913600520 scopus 로고    scopus 로고
    • Emerging roles of regulatory T cells in tumour progression and metastasis
    • Halvorsen EC, Mahmoud SM, Bennewith KL. Emerging roles of regulatory T cells in tumour progression and metastasis. Cancer Metastasis Rev 2014;33:1025-1041.
    • (2014) Cancer Metastasis Rev , vol.33 , pp. 1025-1041
    • Halvorsen, E.C.1    Mahmoud, S.M.2    Bennewith, K.L.3
  • 27
    • 84969383282 scopus 로고    scopus 로고
    • Lysis of cancer cells by highly purified T regulatory cells engaged via an EpCAM/CD3-bispecific BiTE antibody
    • Münz M, et al. Lysis of cancer cells by highly purified T regulatory cells engaged via an EpCAM/CD3-bispecific BiTE antibody. Cancer Res 2012;72:4841.
    • (2012) Cancer Res , vol.72 , pp. 4841
    • Münz, M.1
  • 28
    • 84929868959 scopus 로고    scopus 로고
    • Crucial role of regulatory T cells in predicting the outcome of the T cell engaging antibody blinatumomab in relapsed and refractory B precursor ALL patients
    • Duell J, et al. Crucial role of regulatory T cells in predicting the outcome of the T cell engaging antibody blinatumomab in relapsed and refractory B precursor ALL patients. Blood 2014;124:2291.
    • (2014) Blood , vol.124 , pp. 2291
    • Duell, J.1
  • 29
    • 17644385543 scopus 로고    scopus 로고
    • Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct
    • Hoffmann P, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 2005;115:98-104.
    • (2005) Int J Cancer , vol.115 , pp. 98-104
    • Hoffmann, P.1
  • 30
    • 79957450612 scopus 로고    scopus 로고
    • Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases
    • Raponi S, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma 2011;52:1098-1107.
    • (2011) Leuk Lymphoma , vol.52 , pp. 1098-1107
    • Raponi, S.1
  • 31
    • 0037851832 scopus 로고    scopus 로고
    • Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
    • Loffler A, et al. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Leukemia 2003;17:900-909.
    • (2003) Leukemia , vol.17 , pp. 900-909
    • Loffler, A.1
  • 32
    • 0037446782 scopus 로고    scopus 로고
    • T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct
    • Dreier T, et al. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol 2003;170:4397-4402.
    • (2003) J Immunol , vol.170 , pp. 4397-4402
    • Dreier, T.1
  • 33
    • 33645007038 scopus 로고    scopus 로고
    • T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
    • Schlereth B, et al. T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Cancer Immunol Immunother 2006;55:503-514.
    • (2006) Cancer Immunol Immunother , vol.55 , pp. 503-514
    • Schlereth, B.1
  • 35
    • 84927667667 scopus 로고    scopus 로고
    • Blinatumomab exposure and pharmacodynamic response in patients with non-Hodgkin lymphoma (NHL)
    • Hijazi Y, et al. Blinatumomab exposure and pharmacodynamic response in patients with non-Hodgkin lymphoma (NHL). J Clin Oncol 2013;31:3051.
    • (2013) J Clin Oncol , vol.31 , pp. 3051
    • Hijazi, Y.1
  • 36
    • 84929896570 scopus 로고    scopus 로고
    • Immunopharmacodynamic response to blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)
    • Schub A, et al. Immunopharmacodynamic response to blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). J Clin Oncol 2013;31:7020.
    • (2013) J Clin Oncol , vol.31 , pp. 7020
    • Schub, A.1
  • 37
    • 49649120397 scopus 로고    scopus 로고
    • Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
    • Bargou R, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008;321:974-977.
    • (2008) Science , vol.321 , pp. 974-977
    • Bargou, R.1
  • 38
    • 84925461494 scopus 로고    scopus 로고
    • Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia
    • Zugmaier G, et al. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J 2014;4:244.
    • (2014) Blood Cancer J , vol.4 , pp. 244
    • Zugmaier, G.1
  • 39
    • 84863522243 scopus 로고    scopus 로고
    • Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
    • Klinger M, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012;119:6226-6233.
    • (2012) Blood , vol.119 , pp. 6226-6233
    • Klinger, M.1
  • 40
    • 79959312575 scopus 로고    scopus 로고
    • Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival
    • Topp MS, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011;29:2493-2498.
    • (2011) J Clin Oncol , vol.29 , pp. 2493-2498
    • Topp, M.S.1
  • 42
    • 79958043675 scopus 로고    scopus 로고
    • Bethesda, MD: National Cancer Institute. Based on November 2014 SEER data submission, posted to the SEER web site, April 2015. Available at:
    • Howlader N, et al. SEER Cancer Statistics Review, 1975-2012. Bethesda, MD: National Cancer Institute. Based on November 2014 SEER data submission, posted to the SEER web site, April 2015. Available at: http://seer.cancer.gov/csr/1975_2012/
    • SEER Cancer Statistics Review, 1975-2012
    • Howlader, N.1
  • 43
    • 79952095577 scopus 로고    scopus 로고
    • Modern therapy of acute lymphoblastic leukemia
    • Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011;29:532-543.
    • (2011) J Clin Oncol , vol.29 , pp. 532-543
    • Bassan, R.1    Hoelzer, D.2
  • 44
    • 84863772728 scopus 로고    scopus 로고
    • Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group
    • Hunger SP, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol 2012;30:1663-1669.
    • (2012) J Clin Oncol , vol.30 , pp. 1663-1669
    • Hunger, S.P.1
  • 45
    • 61849122810 scopus 로고    scopus 로고
    • Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century
    • Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood 2009;113:1408-1411.
    • (2009) Blood , vol.113 , pp. 1408-1411
    • Pulte, D.1    Gondos, A.2    Brenner, H.3
  • 47
    • 78650083131 scopus 로고    scopus 로고
    • Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration
    • Kantarjian HM, et al. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer 2010;116:5568-5574.
    • (2010) Cancer , vol.116 , pp. 5568-5574
    • Kantarjian, H.M.1
  • 48
    • 84875716409 scopus 로고    scopus 로고
    • High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia
    • O'Brien S, et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol 2013;31:676-683.
    • (2013) J Clin Oncol , vol.31 , pp. 676-683
    • O'Brien, S.1
  • 49
    • 84865709936 scopus 로고    scopus 로고
    • Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies
    • Gokbuget N, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 2012;120:1868-1876.
    • (2012) Blood , vol.120 , pp. 1868-1876
    • Gokbuget, N.1
  • 50
    • 84916639631 scopus 로고    scopus 로고
    • Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia
    • Topp MS, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 2014;32:4134-4140.
    • (2014) J Clin Oncol , vol.32 , pp. 4134-4140
    • Topp, M.S.1
  • 51
    • 84871491706 scopus 로고    scopus 로고
    • Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
    • Topp MS, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012;120:5185-5187.
    • (2012) Blood , vol.120 , pp. 5185-5187
    • Topp, M.S.1
  • 52
    • 84929877546 scopus 로고    scopus 로고
    • ®) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia (ALL)
    • ®) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia (ALL). Blood 2014;124:379.
    • (2014) Blood , vol.124 , pp. 379
    • Goekbuget, N.1
  • 53
    • 78651290248 scopus 로고    scopus 로고
    • Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia
    • Handgretinger R, Zugmaier G, Henze G, Kreyenberg H, Lang P, von Stackelberg A. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia 2011;25:181-184.
    • (2011) Leukemia , vol.25 , pp. 181-184
    • Handgretinger, R.1    Zugmaier, G.2    Henze, G.3    Kreyenberg, H.4    Lang, P.5    von Stackelberg, A.6
  • 54
    • 84926099033 scopus 로고    scopus 로고
    • Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
    • Topp MS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2015;16:57-66.
    • (2015) Lancet Oncol , vol.16 , pp. 57-66
    • Topp, M.S.1
  • 55
    • 84903632926 scopus 로고    scopus 로고
    • Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab
    • Schlegel P, et al. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab. Haematologica 2014;99:1212-1219.
    • (2014) Haematologica , vol.99 , pp. 1212-1219
    • Schlegel, P.1
  • 56
    • 9444268741 scopus 로고    scopus 로고
    • A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma
    • Stone MJ, et al. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 1996;88:1188-1197.
    • (1996) Blood , vol.88 , pp. 1188-1197
    • Stone, M.J.1
  • 57
    • 84864544136 scopus 로고    scopus 로고
    • Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma
    • Younes A, et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol 2012;30:2776-2782.
    • (2012) J Clin Oncol , vol.30 , pp. 2776-2782
    • Younes, A.1
  • 58
    • 84863337890 scopus 로고    scopus 로고
    • B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
    • Kochenderfer JN, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012;119:2709-2720.
    • (2012) Blood , vol.119 , pp. 2709-2720
    • Kochenderfer, J.N.1
  • 59
    • 84876005284 scopus 로고    scopus 로고
    • CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia
    • 177ra138
    • Brentjens RJ, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013;5:177ra138.
    • (2013) Sci Transl Med , vol.5
    • Brentjens, R.J.1
  • 60
    • 84929875600 scopus 로고    scopus 로고
    • Final results from a phase 1 study of blinatumomab in patients with relapsed/refractory non-Hodgkin's lymphoma
    • Goebeler ME, et al. Final results from a phase 1 study of blinatumomab in patients with relapsed/refractory non-Hodgkin's lymphoma. Hematol Oncol 2013;31:151-200.
    • (2013) Hematol Oncol , vol.31 , pp. 151-200
    • Goebeler, M.E.1
  • 61
    • 84969405509 scopus 로고    scopus 로고
    • Blinatumomab treatment in relapsed/refractory diffuse large B-cell lymphoma in an open-label, phase 2 study: safety, efficacy and late responses
    • Viardot A, et al. Blinatumomab treatment in relapsed/refractory diffuse large B-cell lymphoma in an open-label, phase 2 study: safety, efficacy and late responses. Hematol Oncol 2015;33:181-243.
    • (2015) Hematol Oncol , vol.33 , pp. 181-243
    • Viardot, A.1
  • 62
    • 0035863406 scopus 로고    scopus 로고
    • Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
    • Vose JM, et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001;19:389-397.
    • (2001) J Clin Oncol , vol.19 , pp. 389-397
    • Vose, J.M.1
  • 63
  • 64
    • 0037142053 scopus 로고    scopus 로고
    • The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
    • Rosenwald A, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-1947.
    • (2002) N Engl J Med , vol.346 , pp. 1937-1947
    • Rosenwald, A.1
  • 65
    • 9144237554 scopus 로고    scopus 로고
    • Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
    • Hans CP, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.
    • (2004) Blood , vol.103 , pp. 275-282
    • Hans, C.P.1
  • 66
    • 27644488026 scopus 로고    scopus 로고
    • Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction
    • Bea S, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005;106:3183-3190.
    • (2005) Blood , vol.106 , pp. 3183-3190
    • Bea, S.1
  • 67
    • 53749093794 scopus 로고    scopus 로고
    • Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma
    • Fu K, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008;26:4587-4594.
    • (2008) J Clin Oncol , vol.26 , pp. 4587-4594
    • Fu, K.1
  • 68
    • 0036739436 scopus 로고    scopus 로고
    • Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma
    • Spaepen K, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002;13:1356-1363.
    • (2002) Ann Oncol , vol.13 , pp. 1356-1363
    • Spaepen, K.1
  • 69
    • 84940040980 scopus 로고    scopus 로고
    • Positron emission tomography (PET) guided therapy of aggressive lymphomas - a randomized controlled trial comparing different treatment approaches based on interim PET results (PETAL trial)
    • Duehrsen U, et al. Positron emission tomography (PET) guided therapy of aggressive lymphomas - a randomized controlled trial comparing different treatment approaches based on interim PET results (PETAL trial). Blood 2014;124:391.
    • (2014) Blood , vol.124 , pp. 391
    • Duehrsen, U.1
  • 70
    • 77957965500 scopus 로고    scopus 로고
    • Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era
    • Gisselbrecht C, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184-4190.
    • (2010) J Clin Oncol , vol.28 , pp. 4184-4190
    • Gisselbrecht, C.1
  • 71
    • 84934925868 scopus 로고    scopus 로고
    • Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the Orcharrd study (OMB110928)
    • van Imhoff GW, et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the Orcharrd study (OMB110928). Blood 2014;124:630.
    • (2014) Blood , vol.124 , pp. 630
    • van Imhoff, G.W.1
  • 72
    • 84902316289 scopus 로고    scopus 로고
    • Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
    • Feldman T, et al. Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma. Br J Haematol 2014;166:77-83.
    • (2014) Br J Haematol , vol.166 , pp. 77-83
    • Feldman, T.1
  • 73
    • 84925587926 scopus 로고    scopus 로고
    • Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies
    • Lesokhin AM, et al. Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. Blood 2014;124:291.
    • (2014) Blood , vol.124 , pp. 291
    • Lesokhin, A.M.1
  • 74
    • 84922348765 scopus 로고    scopus 로고
    • Current therapeutic strategies and new treatment paradigms for follicular lymphoma
    • Kritharis A, Sharma J, Evens AM. Current therapeutic strategies and new treatment paradigms for follicular lymphoma. Cancer Treat Res 2015;165:197-226.
    • (2015) Cancer Treat Res , vol.165 , pp. 197-226
    • Kritharis, A.1    Sharma, J.2    Evens, A.M.3
  • 75
    • 84930701624 scopus 로고    scopus 로고
    • Treatment of chronic lymphocytic leukaemia, where are we heading?
    • O'Brien SMVIII. Treatment of chronic lymphocytic leukaemia, where are we heading? Hematol Oncol 2015;33(Suppl 1):46-49.
    • (2015) Hematol Oncol , vol.33 , pp. 46-49
    • O'Brien, S.M.V.1
  • 76
    • 54049158129 scopus 로고    scopus 로고
    • The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival
    • O'Shea D, et al. The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood 2008;112:3126-3129.
    • (2008) Blood , vol.112 , pp. 3126-3129
    • O'Shea, D.1
  • 77
    • 84933673408 scopus 로고    scopus 로고
    • Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study
    • Roschewski M, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol 2015;16:541-549.
    • (2015) Lancet Oncol , vol.16 , pp. 541-549
    • Roschewski, M.1
  • 78
    • 84931287940 scopus 로고    scopus 로고
    • Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing
    • Kurtz DM, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood 2015;125:3679-3687.
    • (2015) Blood , vol.125 , pp. 3679-3687
    • Kurtz, D.M.1
  • 79
    • 78049392920 scopus 로고    scopus 로고
    • How I treat acute myeloid leukemia
    • Rowe JM, Tallman MS. How I treat acute myeloid leukemia. Blood 2010;116:3147-3156.
    • (2010) Blood , vol.116 , pp. 3147-3156
    • Rowe, J.M.1    Tallman, M.S.2
  • 80
    • 0028909393 scopus 로고
    • Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules
    • Freeman SD, Kelm S, Barber EK, Crocker PR. Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood 1995;85:2005-2012.
    • (1995) Blood , vol.85 , pp. 2005-2012
    • Freeman, S.D.1    Kelm, S.2    Barber, E.K.3    Crocker, P.R.4
  • 81
    • 0036815746 scopus 로고    scopus 로고
    • Siglecs: sialic-acid-binding immunoglobulin-like lectins in cell-cell interactions and signalling
    • Crocker PR. Siglecs: sialic-acid-binding immunoglobulin-like lectins in cell-cell interactions and signalling. Curr Opin Struct Biol 2002;12:609-615.
    • (2002) Curr Opin Struct Biol , vol.12 , pp. 609-615
    • Crocker, P.R.1
  • 82
    • 0024602797 scopus 로고
    • Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties
    • Andrews RG, Singer JW, Bernstein ID. Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. J Exp Med 1989;169:1721-1731.
    • (1989) J Exp Med , vol.169 , pp. 1721-1731
    • Andrews, R.G.1    Singer, J.W.2    Bernstein, I.D.3
  • 83
    • 29444437433 scopus 로고    scopus 로고
    • Siglecs-the major subfamily of I-type lectins
    • Varki A, Angata T. Siglecs-the major subfamily of I-type lectins. Glycobiology 2006;16:1R-27R.
    • (2006) Glycobiology , vol.16 , pp. 1R-27R
    • Varki, A.1    Angata, T.2
  • 84
    • 84903122676 scopus 로고    scopus 로고
    • The past and future of CD33 as therapeutic target in acute myeloid leukemia
    • Laszlo GS, Estey EH, Walter RB. The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev 2014;28:143-153.
    • (2014) Blood Rev , vol.28 , pp. 143-153
    • Laszlo, G.S.1    Estey, E.H.2    Walter, R.B.3
  • 85
    • 0022806814 scopus 로고
    • The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors
    • Andrews RG, Takahashi M, Segal GM, Powell JS, Bernstein ID, Singer JW. The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors. Blood 1986;68:1030-1035.
    • (1986) Blood , vol.68 , pp. 1030-1035
    • Andrews, R.G.1    Takahashi, M.2    Segal, G.M.3    Powell, J.S.4    Bernstein, I.D.5    Singer, J.W.6
  • 86
    • 0026594439 scopus 로고
    • Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures
    • La Russa VF, et al. Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures. Exp Hematol 1992;20:442-448.
    • (1992) Exp Hematol , vol.20 , pp. 442-448
    • La Russa, V.F.1
  • 87
    • 30144433084 scopus 로고    scopus 로고
    • A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing
    • Hernandez-Caselles T, et al. A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing. J Leukoc Biol 2006;79:46-58.
    • (2006) J Leukoc Biol , vol.79 , pp. 46-58
    • Hernandez-Caselles, T.1
  • 88
    • 18244428964 scopus 로고    scopus 로고
    • Differences in CD33 intensity between various myeloid neoplasms
    • Jilani I, et al. Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol 2002;118:560-566.
    • (2002) Am J Clin Pathol , vol.118 , pp. 560-566
    • Jilani, I.1
  • 89
    • 84897019168 scopus 로고    scopus 로고
    • CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330
    • Krupka C, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood 2014;123:356-365.
    • (2014) Blood , vol.123 , pp. 356-365
    • Krupka, C.1
  • 91
    • 28844456971 scopus 로고    scopus 로고
    • Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia
    • Taussig DC, et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 2005;106:4086-4092.
    • (2005) Blood , vol.106 , pp. 4086-4092
    • Taussig, D.C.1
  • 92
    • 84859899567 scopus 로고    scopus 로고
    • Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
    • Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 2012;119:6198-6208.
    • (2012) Blood , vol.119 , pp. 6198-6208
    • Walter, R.B.1    Appelbaum, F.R.2    Estey, E.H.3    Bernstein, I.D.4
  • 93
    • 84881305790 scopus 로고    scopus 로고
    • A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
    • Petersdorf SH, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 2013;121:4854-4860.
    • (2013) Blood , vol.121 , pp. 4854-4860
    • Petersdorf, S.H.1
  • 94
    • 84859911350 scopus 로고    scopus 로고
    • Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
    • Castaigne S, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012;379:1508-1516.
    • (2012) Lancet , vol.379 , pp. 1508-1516
    • Castaigne, S.1
  • 95
    • 84897018823 scopus 로고    scopus 로고
    • Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML
    • Laszlo GS, et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. Blood 2014;123:554-561.
    • (2014) Blood , vol.123 , pp. 554-561
    • Laszlo, G.S.1
  • 96
    • 84958748868 scopus 로고    scopus 로고
    • Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3-BiTE(R) antibody construct AMG 330: reversing a T-cell induced immune escape mechanism
    • [E-pub ahead of print].
    • Krupka C, et al. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3-BiTE(R) antibody construct AMG 330: reversing a T-cell induced immune escape mechanism. Leukemia 2015 [E-pub ahead of print].
    • (2015) Leukemia
    • Krupka, C.1
  • 97
    • 84938252275 scopus 로고    scopus 로고
    • T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment
    • Schnorfeil FM, et al. T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. J Hematol Oncol 2015;8:93.
    • (2015) J Hematol Oncol , vol.8 , pp. 93
    • Schnorfeil, F.M.1
  • 99
    • 0034627152 scopus 로고    scopus 로고
    • Ep-CAM overexpression in breast cancer as a predictor of survival
    • Gastl G, Spizzo G, Obrist P, Dunser M, Mikuz G. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 2000;356:1981-1982.
    • (2000) Lancet , vol.356 , pp. 1981-1982
    • Gastl, G.1    Spizzo, G.2    Obrist, P.3    Dunser, M.4    Mikuz, G.5
  • 100
    • 4043147142 scopus 로고    scopus 로고
    • High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer
    • Spizzo G, et al. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 2004;86:207-213.
    • (2004) Breast Cancer Res Treat , vol.86 , pp. 207-213
    • Spizzo, G.1
  • 101
    • 4143074922 scopus 로고    scopus 로고
    • EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy
    • Osta WA, et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 2004;64:5818-5824.
    • (2004) Cancer Res , vol.64 , pp. 5818-5824
    • Osta, W.A.1
  • 102
    • 33750165279 scopus 로고    scopus 로고
    • Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer
    • Spizzo G, et al. Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol 2006;103:483-488.
    • (2006) Gynecol Oncol , vol.103 , pp. 483-488
    • Spizzo, G.1
  • 103
    • 59749103834 scopus 로고    scopus 로고
    • Nuclear signalling by tumour-associated antigen EpCAM
    • Maetzel D, et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 2009;11:162-171.
    • (2009) Nat Cell Biol , vol.11 , pp. 162-171
    • Maetzel, D.1
  • 104
    • 67651003100 scopus 로고    scopus 로고
    • The emerging role of EpCAM in cancer and stem cell signaling
    • Munz M, Baeuerle PA, Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 2009;69:5627-5629.
    • (2009) Cancer Res , vol.69 , pp. 5627-5629
    • Munz, M.1    Baeuerle, P.A.2    Gires, O.3
  • 105
    • 67651165121 scopus 로고    scopus 로고
    • Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release
    • Amann M, et al. Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release. J Immunother 2009;32:452-464.
    • (2009) J Immunother , vol.32 , pp. 452-464
    • Amann, M.1
  • 106
    • 54849440117 scopus 로고    scopus 로고
    • Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans
    • Amann M, et al. Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans. Cancer Immunol Immunother 2009;58:95-109.
    • (2009) Cancer Immunol Immunother , vol.58 , pp. 95-109
    • Amann, M.1
  • 107
    • 84867733430 scopus 로고    scopus 로고
    • A phase I study of EpCAM/CD3-bispecific antibody (MT110) in patients with advanced solid tumors
    • Fiedler WM, et al. A phase I study of EpCAM/CD3-bispecific antibody (MT110) in patients with advanced solid tumors. J Clin Oncol 2012;30:2504.
    • (2012) J Clin Oncol , vol.30 , pp. 2504
    • Fiedler, W.M.1
  • 108
    • 74249122446 scopus 로고    scopus 로고
    • Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody
    • Osada T, et al. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. Br J Cancer 2010;102:124-133.
    • (2010) Br J Cancer , vol.102 , pp. 124-133
    • Osada, T.1
  • 109
    • 84969406844 scopus 로고    scopus 로고
    • In vitro MABEL approach for nonclinical safety assessment of MEDI-565 (MT111)
    • Ryan PC, et al. In vitro MABEL approach for nonclinical safety assessment of MEDI-565 (MT111). ALTEX Proc 2012;1:85-87.
    • (2012) ALTEX Proc , vol.1 , pp. 85-87
    • Ryan, P.C.1
  • 110
    • 84957631975 scopus 로고    scopus 로고
    • Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion for relapsed/refractory gastrointestinal (GI) adenocarcinoma
    • TPS3097
    • De Vries E, et al. Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion for relapsed/refractory gastrointestinal (GI) adenocarcinoma. J Clin Oncol 2015;33:TPS3097.
    • (2015) J Clin Oncol , vol.33
    • De Vries, E.1
  • 111
    • 67449097665 scopus 로고    scopus 로고
    • Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA
    • Lutterbuese R, et al. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. J Immunother 2009;32:341-352.
    • (2009) J Immunother , vol.32 , pp. 341-352
    • Lutterbuese, R.1
  • 112
    • 78651382134 scopus 로고    scopus 로고
    • Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110
    • Petsch S, et al. Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110. MAbs 2011;3:31-37.
    • (2011) MAbs , vol.3 , pp. 31-37
    • Petsch, S.1
  • 113
    • 84871360414 scopus 로고    scopus 로고
    • Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens
    • Friedrich M, et al. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens. Mol Cancer Ther 2012;11:2664-2673.
    • (2012) Mol Cancer Ther , vol.11 , pp. 2664-2673
    • Friedrich, M.1
  • 114
    • 84930415352 scopus 로고    scopus 로고
    • CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1
    • Osada T, Patel SP, Hammond SA, Osada K, Morse MA, Lyerly HK. CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. Cancer Immunol Immunother 2015;64:677-688.
    • (2015) Cancer Immunol Immunother , vol.64 , pp. 677-688
    • Osada, T.1    Patel, S.P.2    Hammond, S.A.3    Osada, K.4    Morse, M.A.5    Lyerly, H.K.6
  • 115
    • 84969385203 scopus 로고    scopus 로고
    • ®) in human EpCAM-positive tumor bearing mice
    • ®) in human EpCAM-positive tumor bearing mice. Eur J Cancer 2014;50:174.
    • (2014) Eur J Cancer , vol.50 , pp. 174
    • Warnders, F.J.1
  • 116
    • 84920833141 scopus 로고    scopus 로고
    • CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas
    • Oberst MD, et al. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. MAbs 2014;6:1571-1584.
    • (2014) MAbs , vol.6 , pp. 1571-1584
    • Oberst, M.D.1
  • 117
    • 77955433583 scopus 로고    scopus 로고
    • T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells
    • Lutterbuese R, et al. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proc Natl Acad Sci USA 2010;107:12605-12610.
    • (2010) Proc Natl Acad Sci USA , vol.107 , pp. 12605-12610
    • Lutterbuese, R.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.